Eric Hedrick
About
Eric Hedrick is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics.
According to data from OpenAlex, Eric Hedrick has authored 39 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 19 papers in Pathology and Forensic Medicine and 18 papers in Genetics. Recurrent topics in Eric Hedrick's work include Chronic Lymphocytic Leukemia Research (18 papers), Lymphoma Diagnosis and Treatment (18 papers) and Colorectal Cancer Treatments and Studies (12 papers). Eric Hedrick is often cited by papers focused on Chronic Lymphocytic Leukemia Research (18 papers), Lymphoma Diagnosis and Treatment (18 papers) and Colorectal Cancer Treatments and Studies (12 papers). Eric Hedrick collaborates with scholars based in United States, Australia and China. Eric Hedrick's co-authors include Axel Grothey, Daniel J. Sargent, Mary M. Sugrue, Mark Kozloff, David M. Purdie, Wei Dong, Ramesh K. Ramanathan, Barrett H. Childs, John D. Hainsworth and Jeff P. Sharman and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.
In The Last Decade
Eric Hedrick
39 papers receiving 4.0k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Eric Hedrick United States | 24 | 2.2k | 2.0k | 1.4k | 838 | 757 | 39 | 4.1k | ||
| Chang‐Ok Suh South Korea | 38 | 1.6k 0.7× | 1.3k 0.7× | 889 0.6× | 433 0.5× | 1.3k 1.7× | 250 | 4.8k | ||
| M. S. Czuczman United States | 24 | 2.5k 1.1× | 3.7k 1.9× | 2.3k 1.6× | 717 0.9× | 334 0.4× | 62 | 5.6k | ||
| Karim Belhadj France | 25 | 1.6k 0.7× | 2.3k 1.2× | 779 0.5× | 696 0.8× | 468 0.6× | 101 | 3.6k | ||
| Achiel Van Hoof Belgium | 18 | 1.3k 0.6× | 1.9k 1.0× | 918 0.6× | 375 0.4× | 388 0.5× | 33 | 2.6k | ||
| Luigi Rigacci Italy | 28 | 1.6k 0.7× | 3.1k 1.6× | 809 0.6× | 208 0.2× | 798 1.1× | 144 | 4.0k | ||
| Rémy Gressin France | 26 | 1.2k 0.5× | 1.7k 0.9× | 880 0.6× | 379 0.5× | 261 0.3× | 109 | 2.5k | ||
| Tamara Shenkier Canada | 27 | 3.4k 1.5× | 3.7k 1.9× | 1.6k 1.1× | 1.0k 1.2× | 1.1k 1.4× | 64 | 6.3k | ||
| Martin Gutierrez United States | 15 | 3.0k 1.3× | 1.2k 0.6× | 480 0.3× | 646 0.8× | 500 0.7× | 44 | 4.0k | ||
| Pierre Feugier France | 26 | 2.2k 1.0× | 3.2k 1.6× | 1.4k 1.0× | 282 0.3× | 335 0.4× | 79 | 3.8k | ||
| Valentin Goede Germany | 27 | 777 0.3× | 1.2k 0.6× | 1.4k 1.0× | 1.0k 1.2× | 445 0.6× | 76 | 3.2k |
Countries citing papers authored by Eric Hedrick
Since
Specialization
Citations
This map shows the geographic impact of Eric Hedrick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Hedrick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Hedrick more than expected).
Fields of papers citing papers by Eric Hedrick
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Eric Hedrick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Hedrick. The network helps show where Eric Hedrick may publish in the future.
Co-authorship network of co-authors of Eric Hedrick
This figure shows the co-authorship network connecting the top 25 collaborators of Eric Hedrick. A scholar is included among the top collaborators of Eric Hedrick based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric Hedrick. Eric Hedrick is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Mato, Anthony R., Boxiong Tang, J. C. Stern, et al.. (2020). A Clinical Practice Comparison of Overall Survival, Time-to-Next-Treatment, and Time-to-Treatment-Discontinuation Among CLL/SLL Patients Receiving First-Line Ibrutinib with and without a Del(17p) Mutation. Blood. 136(Supplement 1). 1–3.
2.
Italiano, Antoîne, Jean‐Charles Soria, Maud Toulmonde, et al.. (2018). Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. The Lancet Oncology. 19(5). 649–659.
3.
Tam, Constantine S., Hang Quach, Andrew J. Nicol, et al.. (2017). BGB-3111 in Combination with Obinutuzumab in Patients with Chronic Lymphocytic Leukemia and Follicular Lymphoma. Blood. 130. 1745–1745.
4.
Trotman, Judith, Stephen Opat, Paula Marlton, et al.. (2017). BRUTON'S TYROSINE KINASE (BTK) INHIBITOR BGB‐3111 DEMONSTRATES HIGH VERY GOOD PARTIAL RESPONSE (VGPR) RATE IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA (WM). Hematological Oncology. 35(S2). 70–71.
5.
Tam, Constantine S., Judith Trotman, Stephen Opat, et al.. (2016). High Major Response Rate, Including Very Good Partial Responses (VGPR), in Patients (pts) with Waldenstrom Macroglobulinemia (WM) Treated with the Highly Specific BTK Inhibitor Bgb-3111: Expansion Phase Results from an Ongoing Phase I Study. Blood. 128(22). 1216–1216.
6.
Rioux, Nathalie, Heike Keilhack, Blythe Thomson, et al.. (2015). Abstract A135: Physiologically-based pharmacokinetic modeling to support clinical investigation of the EZH2 inhibitor, tazemetostat (EPZ-6438) in INI1-deficient pediatric tumors. Molecular Cancer Therapeutics. 14(12_Supplement_2). A135–A135.
7.
Advani, Ranjana H., Joseph J. Buggy, Jeff P. Sharman, et al.. (2012). Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies. Journal of Clinical Oncology. 31(1). 88–94.
8.
O’Brien, Susan, Jacqueline C. Barrientos, Ian W. Flinn, et al.. (2012). Combination of the Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 with bendamustine (B)/rituximab (R) (BR) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase Ib/II study.. Journal of Clinical Oncology. 30(15_suppl). 6515–6515.
9.
O’Brien, Susan, Jan A. Burger, Kristie A. Blum, et al.. (2011). The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Follow-up of a Phase Ib/II Study. Blood. 118(21). 983–983.
10.
Staudt, Louis M., Kieron Dunleavy, Joseph J. Buggy, et al.. (2011). The Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 Modulates Chronic Active BCR Signaling and Induces Tumor Regression in Relapsed/Refractory ABC DLBCL. Blood. 118(21). 2716–2716.
11.
Grothey, Axel, Mary M. Sugrue, David M. Purdie, et al.. (2008). Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE). Journal of Clinical Oncology. 26(33). 5326–5334.
12.
Grothey, Axel, Eric Hedrick, R. Mass, et al.. (2008). Response-Independent Survival Benefit in Metastatic Colorectal Cancer: A Comparative Analysis of N9741 and AVF2107. Journal of Clinical Oncology. 26(2). 183–189.
13.
Grothey, Axel, Mary M. Sugrue, Eric Hedrick, et al.. (2007). 3021 POSTER Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): results from a large observational study (BRiTE). European Journal of Cancer Supplements. 5(4). 241–242.
14.
Oberg, Ann L., et al.. (2006). NCCTG phase II trial of bevacizumab, gemcitabine, oxaliplatin in patients with metastatic pancreatic adenocarcinoma. Journal of Clinical Oncology. 24(18_suppl). 4113–4113.
15.
Hedrick, Eric, et al.. (2004). Post-progression therapy (PPT) effect on survival in AVF2107, a phase III trial of bevacizumab in first-line treatment of metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 22(14_suppl). 3517–3517.
16.
Wang, Eunice S., David J. Straus, Julie Teruya‐Feldstein, et al.. (2003). Intensive chemotherapy with cyclophosphamide, doxorubicin, high‐dose methotrexate/ifosfamide, etoposide, and high‐dose cytarabine (CODOX‐M/IVAC) for human immunodeficiency virus–associated Burkitt lymphoma. Cancer. 98(6). 1196–1205.
17.
Grillo-López, Antonio J, Eric Hedrick, Michelle Rashford, & Mark Benyunes. (2002). Rituximab: Ongoing and future clinical development. Seminars in Oncology. 29(1). 105–112.
18.
Moskowitz, Craig H., Stephen D. Nimer, Andrew D. Zelenetz, et al.. (2001). A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 97(3). 616–623.
19.
Straus, David, et al.. (2001). Cyclophosphamide/Fludarabine (CF) is Active in the Treatment of Mantle Cell Lymphoma. Leukemia & lymphoma. 42(5). 1015–1022.
20.
Kewalramani, Tarun, Andrew D. Zelenetz, Eric Hedrick, et al.. (2000). High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis. Blood. 96(7). 2399–2404.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Chang‐Ok Suh Breakdown of academic impact, for papers by M. S. Czuczman Breakdown of academic impact, for papers by Karim Belhadj Breakdown of academic impact, for papers by Achiel Van Hoof Breakdown of academic impact, for papers by Luigi Rigacci Breakdown of academic impact, for papers by Rémy Gressin Breakdown of academic impact, for papers by Tamara Shenkier Breakdown of academic impact, for papers by Martin Gutierrez Breakdown of academic impact, for papers by Pierre Feugier Breakdown of academic impact, for papers by Valentin Goede